EU Drug Watchdog Opens Safety Review into Anxiety Medicine Deanxit

The European Medicines Agency (EMA) has initiated a formal safety review of Deanxit, a widely prescribed combination medicine used to treat depression and anxiety. The evaluation is being handled by the agency’s Pharmacovigilance Risk Assessment Committee—known universally across the EU bubble as PRAC, an acronym that sounds more like a piece of flatpack furniture than a panel of senior toxicologists and clinicians. Deanxit pairs two active pharmaceutical ingredients: flupentixol, an antipsychotic, and melitracen, a tricyclic antidepressant. PRAC has stepped in to examine the existing evidence surrounding the drug combination.

For patients and doctors, safety reviews can determine whether a medicine stays on pharmacy shelves, has its recommended dosages adjusted, or requires updated warnings on patient leaflets. When European regulators open a review into a long-standing treatment, it often signals emerging data or persistent safety questions raised by national authorities. While the opening of an inquiry does not mean the medicine will be withdrawn or restricted, it initiates a high-stakes scientific audit that can reshape prescribing habits across dozens of healthcare systems simultaneously.

In the intricate machinery of EU healthcare regulation, PRAC is where pharmacology meets pan-European bureaucracy. While marketing approvals grant drugs access to national markets, pharmacovigilance is the institutional safeguard tasked with monitoring whether real-world use reveals unforeseen hazards. Operating out of the EMA in Amsterdam, PRAC operates with clinical detachment: member state experts evaluate reports submitted by national agencies and manufacturers, weighing statistical risks against clinical benefits in a process that is deliberately insulated from political noise.

PRAC will examine the available clinical data, trial results, and post-marketing safety reports for flupentixol and melitracen. Once its scientific assessment concludes, the committee will formulate a recommendation—ranging from maintaining the status quo to revising prescribing advice, restricting indications, or suspending authorisations. That recommendation will then pass through the EMA’s higher governance bodies before landing on the European Commission's desk for an EU-wide legal decision.